

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Complete if Known		
			Application Number	10/806,495	
			Filing Date	03/22/2004	
			First Named Inventor	Chang et al.	
			Art Unit	1714	
			Examiner Name	Not yet assigned	
Sheet	1	of	4	Attorney Docket Number	29329.749.201

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
RH		US-4,605,701	08/12/1986	Harada et al.	
		US-5,380,522	01/10/1995	Day	
		US-5,447,726	09/05/1995	Nomura	
		US-5,487,888	01/30/1996	Mandeville III, et al.	
		US-5,496,545	03/05/1996	Holmes-Farley et al.	
		US-5,667,775	09/16/1997	Holmes-Farley et al.	
		US-5,698,662	12/16/1997	Stoelwinder et al.	
		US-5,702,696	12/30/1997	Mandeville III, et al.	
		US-5,968,499	10/19/1999	Hider et al.	
		US-5,980,881	11/09/1999	Mitsuka et al.	
		US-5,985,938	11/16/1999	Holmes-Farley et al.	
		US-6,007,803	12/28/1999	Mandeville III et al.	
		US-6,034,129	03/07/2000	Mandeville III et al.	
		US-6,060,604	05/09/2000	Yang et al.	
		US-6,129,910	10/10/2000	Holmes-Farley et al.	
		US-6,132,706	10/17/2000	Hider et al.	
		US-6,180,094	01/30/2001	Sasaki et al.	
		US-6,281,252	08/28/2001	Holmes-Farley et al.	
		US-6,383,518	05/07/2002	Matsuda et al.	
		US-6,423,754	07/23/2002	Holmes-Farley et al.	
		US-6,475,510	11/05/2002	Venkatesh et al.	
		US-6,509,013	01/21/2003	Holmes-Farley et al.	
		US-6,566,407	05/20/2003	Holmes-Farley et al.	
		US-6,593,366	07/15/2003	Mandeville III et al.	
		US-6,696,087	02/24/2004	Matsuda et al.	
		US-6,726,905	04/27/2004	Mandeville III et al.	
		US-6,733,780	05/11/2004	Tyler et al.	
RH		US-6,767,549	07/27/2004	Mandeville III et al.	

Examiner Signature	<i>[Signature]</i>	Date Considered	10/30/06
-----------------------	--------------------	--------------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known		
				Application Number	10/806,495	
				Filing Date	03/22/2004	
				First Named Inventor	Chang et al.	
				Art Unit	1714	
				Examiner Name	Not yet assigned	
Sheet	2	of	4	Attorney Docket Number		29329.749.201

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
PH		US-2002/0034723	03/21/2002	Leinenbach et al.	
		US-2002/0064511	05/30/2002	Simon et al.	
		US-2002/0146386	10/10/2002	Simon et al.	
		US-2002/0168333	11/14/2002	Burke	
		US-2002/0182168	12/05/2002	Holmes-Farley	
		US-2002/0187120	12/12/2002	Holmes-Farley et al.	
		US-2002/0187121	12/12/2002	Burke	
		US-2003/0039627	02/27/2003	Holmes-Farley et al.	
		US-2003/0049226	03/13/2003	Burke et al.	
		US-2003/0078366	04/24/2003	McDonnell et al.	
		US-2003/0091530	05/15/2003	Goto et al.	
		US-2003/0092782	05/15/2003	Goto et al.	
		US-2004/0018169	01/29/2004	Holmes-Farley et al.	
		US-2004/0059065	03/25/2004	Goto et al.	
		US-2004/0120922	06/24/2004	Burke	
		US-2004/0170600	09/02/2004	Simon et al.	
PH		US-2004/0194334	10/07/2004	Rea	

Examiner Signature		Date Considered	2/3/06
-----------------------	---	--------------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known		
				Application Number	10/806,495	
				Filing Date	03/22/2004	
				First Named Inventor	Chang et al.	
				Art Unit	1714	
Examiner Name	Not yet assigned					
Sheet	3	of	4	Attorney Docket Number	29329.749.201	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ² - Number ³ - Kind Code ⁴ (if known)				
RM		EP 0373852 B1	10/26/1994	Smith Kline & French Laboratories Limited		
		EP 0741756 B1	11/13/1996	DSM N.V.		
		EP 0997148 B1	05/03/2000	Chugai Seiyaku Kabushiki Kaisha		
		EP 1153940 A1	11/14/2001	Chugai Seiyaku Kabushiki Kaisha		
		EP 1283046 A1	02/12/2003	Hisamitsu Pharmaceuticals Co., Inc.		
		EP 1304104 A2	04/23/2003	Chugai Seiyaku Kabushiki Kaisha		
		WO 93/14147 A1	07/22/1993	DSM N.V.		
		WO 95/05184 A1	02/23/1995	Geltex Pharmaceuticals, Inc.		
		WO 95/19384 A1	07/20/1995	E.I. Du Pont de Nemours and Company; The Du Pont Merck Pharmaceutical company		
		WO 95/20619 A1	08/03/1995	DSM N.V.		
		WO 98/42355 A1	10/01/1998	Geltex Pharmaceuticals, Inc.		
		WO 99/40990 A1	08/19/1999	Kofinas, Peter; Kioussis, Dimitri R.		
		WO 01/28527 A2	04/26/2001	Geltex Pharmaceuticals, Inc.		
RM		WO 2004/037274 A1	05/06/2004	Genzyme Corporation		
Examiner Signature				Date Considered	9/30/06	


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/806,495
				Filing Date	03/22/2004
				First Named Inventor	Chang et al.
				Art Unit	1714
				Examiner Name	Not yet assigned
Sheet	4	of	4	Attorney Docket Number	29329.749.201

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
mf		BREZINA, B. et al., "Acid loading during treatment with sevelamer hydrochloride: mechanisms and clinical implications". <i>Kidney International</i> , (2004), 66:S39-S45.	
		CHANG, H.T. et al., US Patent Application No. 10/701,385 entitled "Polyamine polymers", filed 11/03/2003 (WSGR Docket No. 29329.703.201).	
		CHERTOW, G.M. et al. "Long-term effects of sevelamer hydrochloride on the calcium x phosphate product nad lipid profile of haemodialysis patients". <i>Nephrology Dialysis Transplantation</i> , (1994), 14:2907-2914.	
		HAGMAIER, V. et al., "Test of efficacy of an oxalate-binding anion exchanger Colestid in healthy subjects for use in idiopathic calcium-oxalate urolithiasis". <i>Helvica Chirurgica Acta</i> , (August 1981), 48(3-4):421-424.	X
		ROSS, E.A. et al., "Synthesis of molecularly imprinted polymers (MIPs) for phosphate binding". Published in the abstract list of Renal Week Conference (September 20, 2004), ASN.	
mf		SLATOPOLSKY, E.A. et al., "RenaGel [®] , a nonabsorbed calcium-and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone". <i>Kidney International</i> , (1999), 55:299-307.	

Examiner signature		Date Considered	4/30/06
--------------------	---	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.


This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

 <p>Substitute for form 1449/PTO</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p><i>(Use as many sheets as necessary)</i></p>				Complete if Known	
				Application Number	10/806,495
				Filing Date	March 22, 2004
				First Named Inventor	Han Ting Chang
				Art Unit	1714
				Examiner Name	Not Yet Assigned
Sheet	1	of	1	Attorney Docket Number	29329-749.201

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

Examiner Signature		Date Considered	10/30/06
-----------------------	---	--------------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/806,495
				Filing Date	March 22, 2004
				First Named Inventor	Han Ting Chang
				Art Unit	1713
				Examiner Name	Robert D. Harlan
Sheet	1	Of	1	Attorney Docket Number	29329-749.201

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
KH	1.	US 2005/0096438 A1	05-05-2005	Chang et al.	
	2.	US 2005/0131138 A1	06-16-2005	Connor et al.	
	3.	US 2005/0147580 A1	07-07-2005	Connor et al.	
	4.	US 2005/0239901 A1	10-27-2005	Chang et al.	
	5.	US 2005/0165190 A1	07-28-2005	Chang et al.	
KH	6.	US 4,734,200	03-29-1988	Wes Berry	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
KH	7.	WO 94/27619 A1	12-08-1994	Geltex, Inc.		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
KH	8.	Klapper, M. et al., "Poly(methylene amine): A Polymer with the Maximum Possible Number of Amino Groups on a Polymer Backbone", <i>Angew. Chem. Int. Ed.</i> , Vol. 42 (2003), pp. 4687-4690.	
Kh	9.	Zimmer, A. et al., "Ligand Synthesis and Metal Complex Formation of 1,2,3-Triaminopropane", <i>Eur. J. Inorg. Chem.</i> , July 1998, pp. 2079-2086.	

Examiner Signature	<i>Robert Harlan</i>	Date Considered	10/30/06
--------------------	----------------------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/806,495
				Filing Date	March 22, 2004
				First Named Inventor	Han Ting Chang
				Art Unit	1713
				Examiner Name	Robert D. Harlan
Sheet	1	Of	1	Attorney Docket Number	29329-749.201

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ² - Number ³ - Kind Code ⁴ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
MM	10.	DE 10305807 A1 (In German, with English Abstract)	08-26-2004	BASF AG et al.		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
MM	11.	REISS, Guido J. et al. 2000. Protonation products of pentaamino-pentane as novel building blocks for hydrogen-bonded networks. <i>Acta Cryst.</i> C56: 284-288.	
MM	12.	ZIMMER, Anja et al. 2001. Complex Formation of Ni ^{II} , Cu ^{II} , Pd ^{II} , and Co ^{III} with 1,2,3,4-Tetraaminobutane. <i>Chem. Eur. J.</i> 7(4): 917-931.	

Examiner Signature		Date Considered	10/30/06
--------------------	---	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08 (07/05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/806,495
				Filing Date	March 22, 2004
				First Named Inventor	Han Ting Chang
				Art Unit	1713
				Examiner Name	Robert D. Harlan
Sheet	1	Of	5	Attorney Docket Number	29329-749.201

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
RM	13.	US 3,308,020	03-07-1967	Wolf et al.		
	14.	US 3,499,960	03-10-1970	Macek et al.		
	15.	US 3,974,272	08-10-1976	Polli et al.		
	16.	US 4,027,009	05-31-1977	Grier et al.		
	17.	US 4,410,688	10-18-1983	Denkewalter et al.		
	18.	US 4,507,466	03-26-1985	Tomalia et al.		
	19.	US 4,558,120	12-10-1985	Tomalia et al.		
	20.	US 4,568,737	02-04-1986	Tomalia et al.		
	21.	US 4,587,329	05-06-1986	Tomalia et al.		
	22.	US 4,599,400	07-08-1986	Tomalia et al.		
	23.	US 4,631,337	12-23-1986	Tomalia et al.		
	24.	US 4,690,985	09-01-1987	Tomalia et al.		
	25.	US 4,737,550	04-12-1988	Tomalia		
	26.	US 4,747,881	05-31-1988	Shaw et al.		
	27.	US 4,902,501	02-20-1990	Bandi et al.		
	28.	US 5,091,175	02-25-1992	Imondi et al.		
	29.	US 5,254,669	10-19-1993	Blackborow		
	MH	30.	US 6,361,768 B1	03-26-2002	Galleguillos et al.	
		31.	US 6,646,083 B2	11-11-2003	Hirano et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ² - Number ³ - Kind Code ⁴ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁵
RM	32.	EP 0575596 B1	12-29-1993	DSM N.V.		
	33.	EP 0672703 A1	09-20-1995	DSM N.V.		

Examiner Signature		Date Considered	06/30/06
--------------------	--	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/806,495
				Filing Date	March 22, 2004
				First Named Inventor	Han Ting Chang
				Art Unit	1713
				Examiner Name	Robert D. Harlan
Sheet	2	Of	5	Attorney Docket Number	29329-749.201

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ² - Number ² - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ³
RM	34.	EP 0707611 B1	04-24-1996	DSM N.V.		
	35.	EP 0793960 B1	08-01-2001	Mitsubishi Chemical Corporation		
	36.	EP 1209146 B1 (in German with English Abstract)	05-29-2002	BASF AG		
	37.	WO 82/00257	02-04-1982	Cerami		
	38.	WO 95/02008 A1	01-19-1995	DSM N.V. et al.		
	39.	WO 97/23514 A1	07-03-1997	DSM N.V. et al.		
	40.	WO 97/49736 A2	12-31-1997	G.D. Searle and Co.		
	41.	WO 99/14297 A1	03-25-1999	The Procter & Gamble Company		
	42.	WO 02/077074 A1	10-03-2002	Firmenich SA		
RM	43.	WO 2005/065291 A2	07-21-2005	Genzyme Corporation		

Examiner Signature	<i>Robert Harlan</i>	Date Considered	10/30/06
--------------------	----------------------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.


This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/806,495
				Filing Date	March 22, 2004
				First Named Inventor	Han Ting Chang
				Art Unit	1713
				Examiner Name	Robert D. Harlan
Sheet	3	Of	5	Attorney Docket Number	29329-749.201

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
144	44.	Barsotti, G. et al. 1979. Anion-Exchange Resins for the Uremic Hyperphosphatemia. <i>Mineral and Electrolyte Metabolism</i> . 2(1): 206.	
	45.	Buhleier, Egon et al. 1978. "Cascade"- and "Nonskid-Chain-like" Syntheses of Molecular Cavity Topologies. <i>Synthesis</i> . 1978(02):155-158.	
	46.	Burke, Steven K. 2000. Renagel®: reducing serum phosphorus in haemodialysis patients. <i>Hospital Medicine</i> . 61(9): 622-627.	
	47.	Burt, Helen M. et al. 1985-86. In Vitro Studies Using Ion Exchange Resins as Potential Phosphate Binders for Renal Failure Patients. <i>Uremia Investigation</i> . 9(1): 35-44.	
	48.	Burt, Helen. M. et al. 1986. Ion-Exchange Resins as Potential Phosphate-Binding Agents for Renal Failure Patients: Effect of the Physicochemical Properties of Resins on Phosphate and Bile Salt Binding. <i>Journal of Pharmaceutical Sciences</i> . 76(5): 379-383.	
	49.	Cholestyramine. 1998. Cholestyramine for oral suspension. Copley Pharmaceutical, Inc. Canton, MA. (Package Insert)	
	50.	Colestid®. 2003. Colestid® micronized colestipol hydrochloride tablets. Pharmacia & Upjohn Company, Kalamazoo, MI. (Package Insert)	
	51.	Coli, L. et al. 1992. Phosphate Removal by Resin Hemoperfusion Efficacy and Biocompatibility of a New Exchange Resin. <i>Biomaterials, Artificial Cells, and Immobilization Biotechnology</i> . 20(5): 1153-1163.	
	52.	De Simone, Renato et al. 1978. New Microporous Cholestyramine Analog for Treatment of Hypercholesterolemia. <i>Journal of Pharmaceutical Sciences</i> . 67(12): 1695-1698.	
144	53.	Grynpas, R. et al. 1986. Organic ion exchange resins as substitutes for aluminum hydroxide gels. <i>Life Support Systems</i> . 4(Suppl. 2): 276-8.	

Examiner Signature		Date Considered	10/30/06
--------------------	---	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/806,495
				Filing Date	March 22, 2004
				First Named Inventor	Han Ting Chang
				Art Unit	1713
				Examiner Name	Robert D. Harlan
Sheet	4	Of	5	Attorney Docket Number	29329-749.201

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
MH	54.	Hagmaier, V. et al. 1981. Investigation of the efficacy of oxalate-binding anionic exchanger Colestid in healthy subjects for use in idiopathic calcium-oxalate-urolithiasis. <i>Helv. Chir. Acta.</i> 48(3/4): 421-424.	
	55.	Hardy, P. et al. 1998. Inhibition of Gastric Secretion by Omeprazole and Efficiency of Calcium Carbonate on the Control of Hyperphosphatemia in Patients on Chronic Hemodialysis. <i>Artificial Organs.</i> 22(7): 569-573.	
	56.	Honda, Yoshiteru et al. 2000. Studies on Adsorption Characteristics of Bile Acids and Methotrexate to a New Type of Anion-Exchange Resin, Colestimide. <i>Chem. Pharm. Bull.</i> 48(7): 978-981.	
	57.	Hurst, P.E. et al. 1963. The Effect of Oral Anion Exchange Resins on FÆCAL Anions. Comparison with Calcium Salts and Aluminum Hydroxide. <i>Clin. Sci.</i> 24: 187-200.	
	58.	Konechnik, Thomas J. et al. 1989. In Vitro Adsorption of Bile Salts by Colestipol Hydrochloride. <i>Pharmaceutical Research.</i> 6(7): 619-623.	
	59.	Kurihara, Satoshi et al. 2005. Effect of MCI-196 (colestilan) as a phosphate binder on hyperphosphatemia in haemodialysis patients: a double-blind, placebo-controlled, short-term trial. <i>Nephrol Dial Transplant.</i> 20(2): 424-430.	
	60.	McGary, T.J. et al. 1984-85. Polycation as an Alternative Osmotic Agent and Phosphate Binder in Peritoneal Dialysis. <i>Uremia Investigation.</i> 8(2): 79-84.	
	61.	Nolan, James P. et al. 1975. Endotoxin Binding by Charged and Uncharged Resins. <i>Proceedings of the Society for Experimental Biology and Medicine.</i> 149: 766-770.	
	62.	Peppas, Nicholas A. et al. 1993. Dendrimers and Star Polymers for Pharmaceutical and Medical Applications. <i>Proceed. Intern. Symp. Control. Rel. Bioact. Mater.</i> 20: 143-144.	
MH	63.	Schneider, H. et al. 1984. Aluminum-free oral phosphate binder. <i>Dep. Nephrol. Hypertension.</i> 1(2): 76-9. (Abstract Only).	

Examiner Signature	<i>Robert D. Harlan</i>	Date Considered	10/30/06
--------------------	-------------------------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/806,495
				Filing Date	March 22, 2004
				First Named Inventor	Han Ting Chang
				Art Unit	1713
				Examiner Name	Robert D. Harlan
Sheet	5	Of	5	Attorney Docket Number	29329-749.201

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
H	64.	Sechet, A. et al. 1999. Inhibition de la secretion gastrique par l'omeprazole et efficacite du carbonate de calcium sur le controle de l'hyperphosphoremie des patients hemodialyses chroniques [Inhibition of gastric secretion by omeprazole and efficacy of calcium carbonate in the control of hyperphosphatemia in patients on maintenance hemodialysis]. <i>Nephrologie</i> . 20(4): 213-216. (Article in French with English Summary)	
	65.	Shataeva L.K. et al. 1982. [Effect of FAF anionite swelling on its sorption properties]. <i>Prikl Biokhim Microbiol</i> . 18(1): 65-70. (in Russian w/ English abstract)	
	66.	Swearingen, Ronald A. et al. 2002. Determination of the binding parameter constants of Renagel® capsules and tablets utilizing the Langmuir approximation at various pH by ion chromatography. <i>Journal of Pharmaceutical and Biomedical Analysis</i> . 29: 195-201.	
	67.	WelChol® Tablets. Licensed from: GelTex Pharmaceuticals, Inc. (Package Insert)	
	68.	Wróng, O.M. 1972. Aluminum Toxicity. <i>Lancet</i> . 2(7772): 334-5.	
M	69.	Wrong, O.M. 1973. Anion-Exchange Resins in Treatment of Uræmic Acidosis and Hyperphosphatæmia. <i>Lancet</i> . 1(7801):493.	

Examiner Signature	<i>Robert D. Harlan</i>	Date Considered	6/30/06
--------------------	-------------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/806,495
				Filing Date	March 22, 2004
				First Named Inventor	Han Ting Chang
				Art Unit	1713
				Examiner Name	Robert D. Harlan
Sheet	1	Of	2	Attorney Docket Number	29329-749.201

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
<i>mt</i>	70.	US 2005/0276781 A1	12-15-2005	Ross et al.	
<i> </i>	71.	US 6,180,754 B1	01-30-2001	Stutts et al.	
<i> </i>	72.	US 6,333,051 B1	12-25-2001	Kabanov et al.	
<i>mt</i>	73.	US 6,362,266 B1	03-26-2002	Buchholz et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ¹ - Number ² - Kind Code ³ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁴
<i>mt</i>	74.	WO 01/38423 A1	05-31-2001	Neste Chemicals OY		
<i> </i>	75.	WO 02/32974 A2	04-25-2002	Fujisawa Pharmaceutical Co., Ltd.		
<i> </i>	76.	WO 02/032974 A3	04-25-2002	Fujisawa Pharmaceutical Co., Ltd.		
<i>mt</i>	77.	WO 2006/040579 A1	04-20-2006	The University Court of the University of Glasgow		

Examiner Signature	<i>mt</i>	Date Considered	<i>04/30/06</i>
--------------------	-----------	-----------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/806,495
				Filing Date	March 22, 2004
				First Named Inventor	Han Ting Chang
				Art Unit	1713
				Examiner Name	Robert D. Harlan
Sheet	2	Of	2	Attorney Docket Number	29329-749.201

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
MH	78.	DANIEL, Marie-Christine, et al. 2003. Supramolecular H-Bonded Assemblies of Redox-Active Metallodendrimers and Positive and Unusual Dendritic Effects on the Recognition of H ₂ PO ₄ . <i>J. Am. Chem. Soc.</i> 125(5): 1150-1151.	
	79.	KIOUSSIS, Dimitri R., et al. 2005. Characterization of anion diffusion in polymer hydrogels used for wastewater remediation. <i>Polymer</i> . 46: 9342-9347.	
	80.	KIOUSSIS, Dimitri R., et al. 2005. Characterization of network morphology in anion binding hydrogels used for wastewater remediation. <i>Polymer</i> . 46: 10167-10172.	
	81.	MAZZEO, Jeffrey R., et al. 1999. A phosphate binding assay for sevelamer hydrochloride by ion chromatography. <i>J. Pharm. Biomed. Anal.</i> 19: 911-915.	
	82.	PANOVA, T.V., et al. 2004. Interaction of Poly(propylenimine) Dendrimers with Polyanionic Hydrogels. <i>Faculty of Chemistry, Moscow State University</i> . 46(5): 783-798. (in Russian with English Abstract)	
MH	83.	THITU, Mari, et al. 2005. Aminic epoxy resin hardeners as reactive solvents for conjugated polymers; polyaniline base/epoxy composites for anticorrosion coatings. <i>Polymer</i> . 46: 6855-6861.	

Examiner Signature	<i>Robert D. Harlan</i>	Date Considered	10/30/06
--------------------	-------------------------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FBES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.